Lower chemo with tumor-fighting cells for stage I-II breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether giving less chemotherapy is safe when patients have high levels of tumor-infiltrating lymphocytes (TILs) — a sign that the body's immune system is already fighting the cancer. It is for women with early-stage, triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that has not spread beyond the breast or nearby lymph nodes.
- Your tumor is triple-negative, meaning it tests negative for estrogen receptors, progesterone receptors, and HER2.
- Your tumor has a certain level of immune cells inside it (called TILs), and you have either a small tumor (T1c) with any TILs, or a slightly larger tumor (T2) with at least half of it made up of TILs.
- You are 18 years or older.
- You have a good performance status (able to do daily activities without much help).
- You have not had any allergic reactions to platinum chemotherapy or taxanes in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.